NCT00637195View on ClinicalTrials.gov

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

PHASE3CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

March 11, 2008

Primary Completion Date

June 20, 2008

Study Completion Date

June 18, 2009

Conditions
Infections, PapillomavirusPapillomavirus Vaccines
Interventions
BIOLOGICAL

Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)

Intramuscular administration, 3 doses.

BIOLOGICAL

Engerix™

Intramuscular administration, 4 doses.

Trial Locations (2)

7100

GSK Investigational Site, La Louvière

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00637195 - Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) | Biotech Hunter | Biotech Hunter